Legal Commentary on the GSK China Bribery Case from a China Law Perspective

ANALYSIS: The Chinese investigation of GlaxoSmithKline should serve as a wake-up call, and the shareholders of companies in China should consider undertaking internal due diligence to ensure that existing compliance programs are properly understood and implemented.

Unlock unlimited access to all Global Investigations Review content